eCQM Title | Urinary Symptom Score Change 6-12 Months After Diagnosis of Benign Prostatic Hyperplasia |
||
---|---|---|---|
eCQM Identifier (Measure Authoring Tool) | 771 | eCQM Version Number | 2.2.000 |
NQF Number | Not Applicable | GUID | 1c05c6c0-8099-4270-83ce-292cf6e35c51 |
Measurement Period | January 1, 20XX through December 31, 20XX | ||
Measure Steward | Large Urology Group Practice Association (LUGPA) | ||
Measure Developer | Large Urology Group Practice Association (LUGPA) | ||
Endorsed By | None | ||
Description |
Percentage of patients with an office visit within the measurement period and with a new diagnosis of clinically significant Benign Prostatic Hyperplasia who have International Prostate Symptoms Score (IPSS) or American Urological Association (AUA) Symptom Index (SI) documented at time of diagnosis and again 6-12 months later with an improvement of 3 points |
||
Copyright |
Limited proprietary coding is contained in the measure specifications for user convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. Large Urology Group Practice Association (LUGPA) and Oregon Urology Institute (OUI) disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT [R]) or other coding contained in the specifications. CPT(R) contained in the Measure specifications is copyright 2007- 2019. American Medical Association. LOINC(R) copyright 2004-2019 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2019 International Health Terminology Standards Development Organisation. ICD-10 copyright 2019 World Health Organization. All Rights Reserved. |
||
Disclaimer |
The performance measure is not a clinical guideline and does not establish a standard of medical care, and has not been tested for all potential applications. THE MEASURE AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. Due to technical limitations, registered trademarks are indicated by (R) or [R]. |
||
Measure Scoring | Proportion | ||
Measure Type | Patient Reported Outcome Performance | ||
Stratification |
None |
||
Risk Adjustment |
None |
||
Rate Aggregation |
None |
||
Rationale |
Benign prostatic hyperplasia (BPH) is one of the most common conditions affecting older men, with a prevalence of 50% by age 60 years and 90% by the ninth decade of life (Medina, Parra, & Moore, 1999). The enlarged gland had been proposed to contribute to the overall lower urinary tract symptoms (LUTS) complex (McVary et al., 2014). Although LUTS secondary to BPH is not often a life-threatening condition, the impact of LUTS/BPH on quality of life can be significant (Wei, Calhoun, & Jacobsen, 2005). The American Urological Association Symptom Index (AUA-SI) and the International Prostate Symptom Score (IPSS) were developed to measure outcomes in studies of different treatments for BPH (Wuerstle et al., 2011). The IPSS uses the same questions as the AUA-SI, but also adds a disease-specific quality of life question (OLeary, 2005). The IPSS was adopted in 1993 by the World Health Organization. It is a reproducible, validated index designed to determine disease severity and response to therapy (D’Silva, Dahm, & Wong, 2014). It includes 3 storage symptom questions (frequency, nocturia, urgency) and four voiding symptoms (feeling of incomplete emptying, intermittency, straining, and a weak stream) as well as a Bother question: If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that? A three-point improvement in the score is considered meaningful (McVary et al., 2014). |
||
Clinical Recommendation Statement |
The symptoms of BPH are LUTS symptoms. There are other disorders with similar symptoms that need to be excluded. History, physical examination, and testing are required prior to a diagnosis of BPH. IPSS by itself is not a reliable diagnostic tool for LUTS suggestive of BPH, but serves as a quantitative measure of LUTS after the diagnosis is established (D’Silva, Dahm, & Wong, 2014). Medical and surgical interventions for BPH recommend a follow up IPSS evaluation to determine effectiveness of treatment. IPSS should be evaluated at the time of diagnosis and after definitive treatment. |
||
Improvement Notation |
A meaningful improvement is a negative 3-point change in the urinary symptom score. The quality improves when a higher proportion of people meet the meaningful improvement definition. |
||
Reference |
D'Silva, K. A., Dahm, P., & Wong, C. L. (2014). Does this man with lower urinary tract symptoms have bladder outlet obstruction? The Rational Clinical Examination: A systematic review. Journal of the American Medical Association, 312(5), 535-542. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25096693 |
||
Reference |
McVary, K. T., Roehrborn, C. G., Avins, A. L., et al. (2014). Management of benign prostatic hyperplasia. Retrieved from http://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014) |
||
Reference |
Medina, J. J., Parra, R. O., & Moore, R. G. (1999). Benign prostatic hyperplasia (the aging prostate). Medical Clinics of North America, 83(5), 1213-1229. Retrieved from http://www.sciencedirect.com/science/article/pii/S0025712505701590 |
||
Reference |
O’Leary, M. P. (2005). Validity of the Bother Score in the evaluation and treatment of symptomatic benign prostatic hyperplasia. Reviews in Urology, 7(1), 1-10. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1477553/ |
||
Reference |
Wei, J., Calhoun, E., & Jacobsen, S. (2005). Urologic diseases in America project: Benign prostatic hyperplasia. Journal of Urology, 173(4), 1256-1261. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15758764 |
||
Reference |
Wuerstle, M. C., Van Den Eeden, S. K., Poon, K. T., et al. (2011). Contribution of common medications to lower urinary tract symptoms in men. Archives of Internal Medicine, 171(18), 1680-1682. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21987200 |
||
Definition |
Clinically significant Benign Prostatic Hyperplasia (BPH) is BPH with lower urinary tract symptoms (LUTS). IPSS - International Prostate Symptom Score AUA-SI - American Urological Association-Symptom Index QOL - Quality of Life score |
||
Guidance |
The IPSS is inclusive of the symptom index score and the quality of life score. The AUA-SI is the symptom index score alone and must be added to the QOL score. The AUA-SI with the QOL equals the IPSS. Both of these are the urinary symptom score. The patient must have a urinary symptom score (USS) within 1 month after initial diagnosis. If more than one USS in the initial one month, then the first USS counts. The patient must have a USS again at 6-12 months after the initial diagnosis and if more than one USS in this time frame, then the last USS counts. Hospitalization within 30 days of Initial BPH Diagnosis refers to a 30-day period between the end of the hospitalization and the clinical office setting BPH diagnosis. This is due to aggravating factors from hospitalization, such as bed rest, medications, surgery, and altered body functions. This eCQM is a patient-based measure. This version of the eCQM uses QDM version 5.5. Please refer to the eCQI resource center (https://ecqi.healthit.gov/qdm) for more information on the QDM. |
||
Transmission Format |
TBD |
||
Initial Population |
Male patients with an initial diagnosis of benign prostatic hyperplasia 6 months prior to, or during the measurement period, and a urinary symptom score assessment within 1 month of initial diagnosis and a follow-up urinary symptom score assessment within 6-12 months, who had a qualifying visit during the measurement period |
||
Denominator |
Equals Initial Population |
||
Denominator Exclusions |
Patients with urinary retention that starts within 1 year of initial BPH diagnosis. Patients with an initial BPH diagnosis that starts during, or within 30 days of hospitalization. Patients with a diagnosis of morbid obesity, or with a BMI Exam >40 before the follow up urinary symptom score. |
||
Numerator |
Patients with a documented improvement of at least 3 points in their urinary symptom score during the measurement period |
||
Numerator Exclusions |
Not Applicable |
||
Denominator Exceptions |
None |
||
Supplemental Data Elements |
For every patient evaluated by this measure also identify payer, race, ethnicity and sex |
( "Patient is Male" ) and "Has Qualifying Encounter" and "Has Qualifying BPH Diagnosis" and "Urinary Symptom Score Within 1 Month after Initial BPH Diagnosis" is not null and "Urinary Symptom Score 6 to 12 Months After Initial BPH Diagnosis" is not null
"Initial Population"
exists ( "Urinary Retention Diagnosis Starts Within 1 Year After Initial BPH Diagnosis" ) or ( "Has Initial BPH Diagnosis Starts During or Within 30 Days After End of Hospitalization" is not null ) or ( "Morbid Obesity Diagnosis or BMI Exam Result Greater Than 40 Starts On or Before Follow Up USS Assessment" )
"Urinary Symptom Score Improvement Greater Than or Equal To 3"
None
None
None
["Assessment, Performed": "American Urological Association Symptom Index [AUASI]"] AUASIAssessment let LastAUASIOnDate: Last(["Assessment, Performed": "American Urological Association Symptom Index [AUASI]"] AUASI where AUASI.relevantDatetime same day as AUASIAssessment.relevantDatetime and AUASI.result is not null sort by relevantDatetime ), LastQOLOnDate: Last(["Assessment, Performed": "If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that [IPSS]"] QOLAssessment where QOLAssessment.relevantDatetime same day as AUASIAssessment.relevantDatetime and QOLAssessment.result is not null sort by relevantDatetime ) return { relevantDatetime: LastAUASIOnDate.relevantDatetime, result: ( LastAUASIOnDate.result as Integer ) + ( LastQOLOnDate.result as Integer ) }
["Physical Exam, Performed": "Estimated BMI greater than 40"] BMIExam with "Urinary Symptom Score 6 to 12 Months After Initial BPH Diagnosis" FollowUpUSSAssessment such that BMIExam.relevantDatetime during "Measurement Period" and BMIExam.relevantDatetime on or before FollowUpUSSAssessment.relevantDatetime and BMIExam.result > 40 'kg/m2'
"Initial Population"
exists ( "Urinary Retention Diagnosis Starts Within 1 Year After Initial BPH Diagnosis" ) or ( "Has Initial BPH Diagnosis Starts During or Within 30 Days After End of Hospitalization" is not null ) or ( "Morbid Obesity Diagnosis or BMI Exam Result Greater Than 40 Starts On or Before Follow Up USS Assessment" )
["Assessment, Performed": "International Prostate Symptom Score [IPSS]"] IPSSAssessment where IPSSAssessment.result is not null return { relevantDatetime: ( IPSSAssessment.relevantDatetime ), result: IPSSAssessment.result as Integer }
"Initial BPH Diagnosis Within 6 Months Before or After Start of Measurement Period Prevalence Period" InitialBPHDiagnosis with ["Encounter, Performed": "Hospital Services for urology care"] InHospitalServices such that InitialBPHDiagnosis.prevalencePeriod starts during Interval[start of InHospitalServices.relevantPeriod, end of InHospitalServices.relevantPeriod + 31 days )
"Initial BPH Diagnosis Within 6 Months Before or After Start of Measurement Period Prevalence Period" is not null
exists ["Encounter, Performed": "Office Visit"] ValidEncounter where ValidEncounter.relevantPeriod during "Measurement Period"
First(["Diagnosis": "Benign prostatic hyperplasia with lower urinary tract symptoms"] NewBPHDiagnosis where NewBPHDiagnosis.prevalencePeriod starts during Interval[start of "Measurement Period" - 6 months, end of "Measurement Period"] )
( "Patient is Male" ) and "Has Qualifying Encounter" and "Has Qualifying BPH Diagnosis" and "Urinary Symptom Score Within 1 Month after Initial BPH Diagnosis" is not null and "Urinary Symptom Score 6 to 12 Months After Initial BPH Diagnosis" is not null
["Diagnosis": "Morbid Obesity"] MorbidObesity with "Urinary Symptom Score 6 to 12 Months After Initial BPH Diagnosis" FollowUpUSSAssessment such that MorbidObesity.prevalencePeriod overlaps "Measurement Period" and MorbidObesity.prevalencePeriod starts on or before FollowUpUSSAssessment.relevantDatetime
exists "Morbid Obesity Diagnosis On or Before Follow Up USS Assessment" or exists "BMI Exam Result Greater Than 40 During Measurement Period and On or Before Follow Up USS Assessment"
"Urinary Symptom Score Improvement Greater Than or Equal To 3"
exists ["Patient Characteristic Sex": "Male"]
["Patient Characteristic Ethnicity": "Ethnicity"]
["Patient Characteristic Payer": "Payer"]
["Patient Characteristic Race": "Race"]
["Patient Characteristic Sex": "ONC Administrative Sex"]
["Diagnosis": "Urinary retention"] UrinaryRetention with "Initial BPH Diagnosis Within 6 Months Before or After Start of Measurement Period Prevalence Period" InitialBPHDiagnosis such that UrinaryRetention.prevalencePeriod starts 1 year or less on or after day of start of InitialBPHDiagnosis.prevalencePeriod
Last("Urinary Symptom Score Tuple Return" LastUSSAssessment with "Initial BPH Diagnosis Within 6 Months Before or After Start of Measurement Period Prevalence Period" InitialBPHDiagnosis such that months between start of InitialBPHDiagnosis.prevalencePeriod and LastUSSAssessment.relevantDatetime in Interval[6, 12] sort by relevantDatetime )
from "Urinary Symptom Score Within 1 Month after Initial BPH Diagnosis" FirstUSSAssessment, "Urinary Symptom Score 6 to 12 Months After Initial BPH Diagnosis" FollowUpUSSAssessment let USSChange: FirstUSSAssessment.result - FollowUpUSSAssessment.result return USSChange
( "Urinary Symptom Score Improvement" USSImprovement where USSImprovement >= 3 ) is not null
"Documented IPSS Assessment Result" union "AUA Symptom Index and Quality of Life Assessment Result"
First("Urinary Symptom Score Tuple Return" InitialUSSAssessment with "Initial BPH Diagnosis Within 6 Months Before or After Start of Measurement Period Prevalence Period" InitialBPHDiagnosis such that InitialUSSAssessment.relevantDatetime 1 month or less on or after day of start of InitialBPHDiagnosis.prevalencePeriod sort by relevantDatetime )
["Patient Characteristic Ethnicity": "Ethnicity"]
["Patient Characteristic Payer": "Payer"]
["Patient Characteristic Race": "Race"]
["Patient Characteristic Sex": "ONC Administrative Sex"]
Measure Set |
None |
---|